Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05865028
PHASE2

A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

Sponsor: Elizabeth J Franzmann

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess whether APG-157 can reduce the tumor size in participants with the study disease. Another purpose is to find out about the effects of APG-157 on certain tumor markers and oral rinses in participants with the study disease.

Official title: Phase II A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2023-05-24

Completion Date

2028-05-24

Last Updated

2026-01-14

Healthy Volunteers

No

Interventions

DRUG

APG-157

Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.

Locations (1)

University of Miami

Miami, Florida, United States